Orchid Pharma has received a clean bill of health for its FY26 standalone financial results. However, the consolidated results came with a modified auditor opinion. To fund capital expenditures and manage debt, they've successfully raised INR 391.8 crore via a Qualified Institutional Placement (QIP).

Orchid Pharma's fourth-quarter profit increased by 10% year over year, reaching ₹306 million. However, the quarterly revenue remained unchanged from last year at approximately ₹2.37 billion.

Orchid Pharma's Q4 earnings increased by 7%, reaching INR 24 crore, with a slight rise in revenue to INR 237.61 crore. However, the full-year (FY23) net profit experienced a significant drop of 79.4%, landing at INR 20.55 crore, and revenue decreased by 12% YoY to INR 811.33 crore.

The National Company Law Tribunal (NCLT) in Chennai has rejected DBS Bank's lease claim against Orchid Pharma, following a hearing during the Corporate Insolvency Resolution Process (CIRP). This ruling, announced on April 2, 2026, did not affect Orchid Pharma's operational or financial status.

Orchid Pharma's credit rating has been lowered by CARE Ratings to BBB-, while maintaining a stable outlook. The short-term ratings remain at A2. Previous ratings were under review, but have now been reaffirmed.